Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Diagnostic accuracy of MRE and ultrasound for Crohn's disease

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Development and validation of a dynamic outcome prediction model for paracetamol-induced acute liver failure: a cohort study.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Edward J Gane
  • Stephen Pianko
  • Stuart K Roberts
  • Alexander J Thompson
  • Stefan Zeuzem
  • Eli Zuckerman
  • Ziv Ben-Ari
  • Graham R Foster
  • Kosh Agarwal
  • Alex L Laursen
  • Jan Gerstoft
  • Wei Gao
  • Hsueh-Cheng Huang
  • Brian Fitzgerald
  • Doreen Fernsler
  • Jerry J Li
  • Anjana Grandhi
  • Hong Liu
  • Feng-Hsiu Su
  • Shuyan Wan
  • Zhen Zeng
  • Huei-Ling Chen
  • Frank J Dutko
  • Bach-Yen T Nguyen
  • Janice Wahl
  • Michael N Robertson
  • Eliav Barr
  • Wendy W Yeh
  • Rebeca M Plank
  • Joan R Butterton
  • Rafael Esteban
Vis graf over relationer

BACKGROUND: New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed. The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibitor) in an 8-week regimen combined with grazoprevir (NS3/4A inhibitor; 100 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir (MK-8408; 60 mg once daily), and to evaluate the safety and tolerability of these combination regimens in individuals infected with genotypes 1, 2, or 3.

METHODS: Part A of these phase 2, randomised, multicentre, open-label, clinical trials enrolled participants from 11 countries, aged 18 years or older, chronically infected with HCV genotypes 1, 2, or 3, with HCV RNA of at least 10 000 IU/mL, without evidence of cirrhosis, who had not received previous treatment for HCV infection. Within each HCV genotype, participants were randomly assigned (1:1:1:1) with a block size of 4, to open-label treatment to one of four treatment groups: grazoprevir (100 mg/day) plus ruzasvir (60 mg/day) plus uprifosbuvir (300 mg/day); grazoprevir (100 mg/day) plus ruzasvir (60 mg/day) plus uprifosbuvir (450 mg/day); grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (300 mg/day); or grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (450 mg/day), according to a computer-generated allocation schedule. Randomisation was centrally implemented using an interactive voice response system and integrated web response system. The primary endpoint was the proportion of participants achieving sustained virological response at 12 weeks (SVR12; HCV RNA less than the lower limit of quantitation at 12 weeks after the end of all study therapy) in the per-protocol analysis set, which included all participants who were randomised and received at least one dose of study drug. The trials are registered with ClinicalTrials.gov, numbers NCT02332707 and NCT02332720.

FINDINGS: 241 participants were randomised between Feb 18, 2015, and March 16, 2015. 240 participants completed 8 weeks of treatment and reached follow-up 12 weeks after the end of treatment. Of the four regimens, grazoprevir plus ruzasvir plus uprifosbuvir 450 mg had the most consistently high SVR12 (>90%) for participants infected with genotype 1 (21 [91%] of 23), genotype 2 (15 [94%] of 16), and genotype 3 (20 [91%] of 22). In particular, among those with genotype 2 infection, the grazoprevir plus ruzasvir plus uprifosbuvir 450 mg regimen had a higher SVR12 (15 [94%] of 16) than the grazoprevir plus ruzasvir plus uprifosbuvir 300 mg regimen (ten [71%] of 14), grazoprevir plus elbasvir plus uprifosbuvir 300 mg regimen (11 [69%] of 16), or grazoprevir plus elbasvir plus uprifosbuvir 450 mg regimen (nine [60%] of 15). Overall, the most common adverse events were headache (55 [23%] of 240), fatigue (47 [20%] of 240), and nausea (32 [13%] of 240). Two (<1%) of 240 participants had serious adverse events (pharyngeal abscess and keratitis), which were not considered drug related by the respective investigators.

INTERPRETATION: These results support further evaluation of the three-drug direct-acting antiviral agent regimen of grazoprevir 100 mg plus ruzasvir 60 mg plus uprifosbuvir 450 mg among a more diverse HCV-infected population, including those with compensated cirrhosis, previous treatment with an interferon-containing regimen, and HCV-HIV co-infection.

FUNDING: Merck & Co, Inc.

OriginalsprogEngelsk
TidsskriftThe Lancet Gastroenterology and Hepatology
Vol/bind2
Udgave nummer11
Sider (fra-til)805-813
Antal sider9
ISSN2468-1253
DOI
StatusUdgivet - nov. 2017

ID: 52621882